Novartis Pauses Cell Therapy Trials After Three Deaths as MS Pill Succeeds in Late-Stage Studies
Three deaths halt Novartis rap-cel trials in autoimmune disease. Positive Phase 3 data for remibrutinib in relapsing MS announced the same day.
/ 26 items
#NVS↓
Novartis Beats Q2 2026 Expectations as New Drugs Offset Generic Pressure
Novartis reported strong Q2 2026 results with $14.41B sales and a core profit beat, driven by Kisqali (+43%) and Scemblix. Full-year guidance reaffirmed despite Entresto patent cliff.
Celcuity’s Revtorpyk Gets FDA Nod, Delivering Strong Results in PIK3CA Wild-Type Breast Cancer
The new treatment, given with fulvestrant with or without palbociclib, nearly quadrupled progression-free survival versus standard therapy.
Novartis to Acquire Myricx Bio for Up to $1.5 Billion to Bolster Next-Gen ADC Pipeline
Novartis is gaining B7-H3 and HER2 ADCs with innovative NMTi technology designed to overcome cancer resistance.
Merck Buys Terns Pharmaceuticals for $6.7 Billion to Boost Blood Cancer Pipeline with Promising CML Drug
Merck is buying Terns Pharmaceuticals for $6.7 billion to add TERN-701, a promising new oral drug for chronic myeloid leukemia (CML). The move strengthens its cancer pipeline as Keytruda patent expiry nears in 2028.
Tempus AI Hits Major Milestone with $1.1 Billion in Contracts
Tempus AI achieves record $1.1 billion in total contract value, partners with 70+ pharmaceutical companies, and reports 31% revenue growth in 2025.